Register Now
Title: PGx – From Basics to Analysis and Interpretation
WHEN: Starting 10 September, 2024 – 1 October, 2024 (virtual 4 week course)
TIME: Every Tuesday at 14:00-15:00 (GMT+2, Central European Time). There is a 15-minute Q&A at the end of each lecture
EXPERTS: Guided by experts in their fields, Hagar Mor-Shaked and Suzanne Drury.
ACCESS TO GENEYX ANALYSIS: In addition, each participant is provided access to the Geneyx platform for training purposes. You can start a new account here
CERTIFICATION: Upon completion of the course, participants will be awarded certification.
Guided Training from Geneyx Experts
Get access to real cases that highlight the scientific principles and tools that are crucial to pharmacogenomic analysis and interpretation in the context of clinical practice.
STUDENTS:
This course is designed for health professionals working in diverse domains; clinical professionals (consultants and trainees) and clinical scientists who require knowledge and hands-on training.
This Four-week course on pharmacogenomics covers history, gene-drug pairs, testing strategies, analysis, reporting, and future implementation in healthcare.
Please note: Previous knowledge is mandatory for the following modules: Basic genetics, Population genetics, and Genetic work-up methodologies.
HOW TO APPLY:
Click here to register for the course.
After registering, you will receive a confirmation email containing information about joining.
PROGRAM AT A GLANCE:
Week 1 | Week 2 | Week 3 | Week 4 |
10 Sep, 2024 | 17 Sep, 2024 | 24 Sep, 2024 | 1 Oct, 2024 |
Introduction to Pharmacogenomics | Gene-Drug Pairs & Testing strategies | Analysis and reporting
| Future Implementation of PGx |
•Introduction/history of PGx •Clinical examples/main therapeutic areas (past/present) •Barriers to implementation to date | •Recommendations & resources •PGx genes and variant types •Laboratory testing strategy (assay types – TaqMan, NGS, long read) | •How to interpret PGx (genotype-report) •Geneyx Platform and examples | •Breaking down barriers to implementation via NGS & clinical decision supprt •Clinical examples (future of PGx – primary, secondary, tertiary care) |
MORE ABOUT THE LECTURERS:
Dr. Hagar Mor Shaked, PhD
CPO at Geneyx. Hagar is one of the leading and experienced clinical genetic experts.
She is an esteemed clinical genetic analyst, with over 10 years of experience in molecular genetics, genomics, and bioinformatics in a clinical and academic setting. As head of bioinformatics at the genetic department of Hadassah University Medical center, she gained expertise in using different NGS methodologies for diagnosing rare diseases, analyzed thousands of clinical exome and genome sequencing tests, and established the largest genomic database in Israel. In addition, she published more than a dozen high-quality academic papers. Hagar holds an MSc in genetic counseling and a PhD. degree in human genetics from the Hebrew University of Jerusalem.
Dr. Suzanne Claire Drury, PhD
Field Application Specialist for EMEA at Geneyx.
Suzie has over 20 years of experience in biotech, NHS, and academia across a range of clinical disciplines. She has focused on the implementation of new genomic technologies in clinical care, including pediatric rare disease, personalized medicine, and non-invasive prenatal diagnosis. Suzie was awarded her PhD at Imperial College London, before progressing her career at the Royal Marsden Hospital London, Great Ormond Street Hospital London, and Congenica Ltd.
